ArticleEye (London, England)2026
Diabetic macular atrophy, a pilot exploration of its characteristics, progression, and visual implications.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo characterise diabetic macular atrophy (DMA) and identify risk factors for progression to retinal pigment epithelium (RPE) and outer retinal atrophy.
methodsIn this retrospective longitudinal cohort study, we analysed 103 eyes from 70 patients with diabetic retinopathy (DR) and DMA, identified between 2015 and 2024. DMA was defined by clear-bordered hypopigmented RPE lesions on fundus photography with corresponding choroidal hypertransmission on optical coherence tomography (OCT). Lesions were classified as focal or diffuse and staged using modified criteria from the Classification of Atrophy Meetings for the geographic atrophy. Longitudinal OCT, fundus photos, and visual acuity were evaluated using time-to-event analysis and linear mixed-effects models.
resultsOver a mean follow-up of 91.9 months, 93% of eyes progressed to complete RPE and outer retinal atrophy (cRORA). Foveal detachment from DR-related macular structural complications, including macular oedema, epiretinal membrane, vitreomacular traction, and retinal detachment, was linked to earlier onset (p < 0.001) and faster progression (p = 0.036) to cRORA. Diffuse-type DMA, more common in females and eyes post-vitrectomy with silicone oil, was associated with worse visual acuity throughout progression (p = 0.010) and at end-stage (p = 0.029). Fundus autofluorescence in DMA revealed a characteristic diffuse hypoautofluorescence surrounding atrophic patch.
conclusionDMA is a vision-threatening, progressive condition in advanced DR. The diffuse-type DMA predicted worse vision throughout DMA progression and end-stage DMA. Foveal detachment of any cause was associated with earlier DMA onset and faster progression to end-stage. Structural macular complications in DR may play a pivotal role in DMA pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.